Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Institut für Pharmakologie und Präventive Medizin
SEVICONTROL-2:
Efficacy and Safety of a sequential therapy change from Candesartan 32 mg to the fixed combination of olmesartan 40 mg/amlodipine 10 mg in patients with poorly controlled moderate hypertension - an open phase IV trial
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
male or female patients \>= 18 years of age
essential hypertension, i. e. systolic office bp \>= 140 mmHg for pre-treated patients or \>= 160 mmHg for untreated patients at screening visit and \>= 160 mmHg at end of wash-out
signed IC
You may not be if
systolic office bp \> 180 mm Hg at screening visit
known hypertensive retinopathy GIII or IV
recent (\< 4 weeks ago) myocardial infarction or indication for coronary or peripheral revascularisation
type I diabetes or poorly controlled (HbA1c \>= 8) type II diabetes
chronic heart failure NYHA III or IV
prior stroke or TIA
creatinine clearance \< 60 ml/min or condition after kidney transplant
moderately or severely impaired liver function (ALT or AST or bilirubin more than double normal value)
women of childbearing potential without highly effective contraception, pregnant or breastfeeding women
concomitant therapy with lithium
hemodynamically relevant mitral or aortic valve stenosis (\>= II°) or hypertrophic obstructive cardiomyopathy
concomitant therapy with strong CYP3A4 inhibitors or inductors
african patients
concomitant severe psychiatric condition that might impair proper intake of study medication
life expectancy \< 6 months
night shift workers
known other mandatory indication for treatment with antihypertensive medications